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University of Padova, ItalyBackground & Aims: The recurrence of type 1 hepatorenal syn- Type 1 HRS develops as a result of a severe reduction of effective
drome has been described in up to 20% of responders to terlipres-
sin and albumin after the discontinuation of the treatment.
Subsequent recurrence of type 1 hepatorenal syndrome may
require long-term treatment with terlipressin and albumin.
Methods:We describe our experience of long-term administra-
tion of terlipressin as a bridge to LT in three patients with cirrho-
sis and recurrent type 1 hepatorenal syndrome. For all three
patients we requested an ‘‘early transplant’’ which is an option
recognized in our country to reduce waiting times for liver
transplantation.
Results: All three patients were transplanted within 2 months of
onset of hepatorenal syndrome. All patients are still alive and
none of them have developed chronic kidney disease.
Conclusions: The outcomes of these patients suggest that long-
term treatment with terlipressin and albumin is effective andwell
tolerated in patients with continuous recurrence of type 1 hepato-
renal syndrome and, therefore, should be considered an absolute
priority criterion in the allocation system for liver transplantation.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
Type 1 hepatorenal syndrome (HRS) is a phenotype of acute renal
failure that often occurs in patients with cirrhosis and ascites.Journal of Hepatology 20
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onitis; CNIs, calcineurin inhibitors.circulating volume due to both an extreme splanchnic arterial
vasodilatation and a reduction of cardiac output [1]. The optimal
and deﬁnitive treatment of type 1 HRS is liver transplantation
(LT). Nevertheless, the prognosis of type 1 HRS is so poor that it
can reduce the probability of undergoing LT. The administration
of terlipressin and albumin has been shown to be effective in
the treatment of type 1 HRS since it can restore renal function
in 35–46% of cases. Additionally, a good response to this treat-
ment is associated with an improvement in survival rates and
outcome of LT. A complete response to terlipressin and albumin
has been deﬁned as a reduction of serum creatinine below
1.5 mg/dl (133 lmol/L) [1]. The length of treatment should be
extended for a maximum of 14 days in patients with partial or
no response [1]. After the withdrawal of treatment type 1 HRS
can recur in up to 20% of the cases [2]. It has been stated that
the recurrence of type 1 HRS can be reverted with a re-treatment
with terlipressin and albumin [1]. This therapeutic strategy can
result in a long-term administration of terlipressin and albumin
until the time of LT in patients with continuous recurrence of
type 1 HRS [3]. Taking into account that neither continuous
recurrence of type 1 HRS nor long-term treatment of type 1
HRS is now considered to be an exception to Model of End-stage
Liver Disease (MELD) score in the organ allocation system, this
policy can negatively affect the outcome after LT [3]. Here we
described three patients with cirrhosis, ascites and continuous
recurrence of type 1 HRS who underwent long-term treatment
with terlipressin and albumin before successfully undergoing LT.Case report
Case 1
In November 2009 a 61-year-old man affected by alcohol-related
cirrhosis (abstinent from 2007), who was regularly followed as an
outpatient by our Unit for refractory ascites, was admitted to our
Liver Unit for spontaneous bacterial peritonitis (SBP) and acute
renal failure (serum creatinine 446 lmol/L; 5.04 mg/dl). On11 vol. 55 j 491–496
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Fig. 2. Model of End Stage Liver Disease (MELD) score, Na-MELD. ‘Actual’
values were calculated on the basis of the serum creatinine value during
treatment. ‘Real’ values were calculated on the basis of the peak value of serum
creatinine during the last episode of type 1 HRS.
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admission, antibiotic therapy was promptly started with a resolu-
tion of SBP. One week before hospitalization serum creatinine
was only lightly increased (128 lmol/L; 1.45 mg/dl), and a diag-
nosis of type 1 HRS was made according to the International Club
of Ascites (ICA) criteria [2], leading to the administration of terli-
pressin by continuous intravenous infusion and i.v. albumin [2].
At the same time, the ongoing administration of propanolol
was discontinued. After the normalization of renal function on
day 15, the treatment was discontinued. Within the following
48 h serum creatinine increased up to 218 lmol/L (2.47 mg/dl)
(Fig. 1), so treatment with terlipressin and albumin was reintro-
duced. A urinary trait infection (UTI) on day 23 further compli-
cated the clinical course of the disease during the following
days causing renewed deterioration of renal function, which
was reverted by increasing the daily dose of terlipressin up to
6 mg. On day 33 the treatment was discontinued after a slow
tapering of the dose of terlipressin. On day 35, in the absence
of a precipitating factor, a new episode of type 1 HRS occurred
leading to the reactivation of treatment with terlipressin and
albumin, and a request for ‘‘early’’ LT was submitted ﬁrst to the
local Committee for LT and then to the organ procurement
agency of our area, the North Italian Transplant (NIT). A request
for an ‘‘early transplant’’ within the NIT can be advanced for an
hospitalized candidate to LT with a MELD score >25. When a
request for an ‘‘early transplant’’ is presented to the NIT, the
transplant center which would receive the graft on a regular basis
can opt to give it to the center which requests an ‘‘early trans-
plant’’, as part of a gentlemanly agreement. At the time of our
request the MELD score and the MELD-Na score, which were cal-
culated based on the value of serum creatinine on day 35 were 19
(‘‘actual’’ MELD score) and 19 (‘‘actual’’ MELD-Na score). Never-
theless, our request was sustained by the fact that the need for
continuous and long-term treatment with terlipressin and0
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Fig. 1. Time course of serum creatinine and treatment with terlipressin and albu
administered at the dose of 20–40 g/day for the duration of treatment with terlipressin. D
a 226 lmol/l value of serum creatinine.
492 Journal of Hepatology 201albumin was recognized and accepted as an exception to MELD
by NIT. Our request was accepted on the basis of a simple evalu-
ation: if the MELD score was calculated by reviving the peak
value of creatinine during the last episode of type 1 HRS the
‘‘real’’ MELD score and the ‘‘real’’ MELD-Na score of the patient
would have been 30 and 34, respectively. On day 55, while still
being treated with terlipressin at the daily dose of 6 mg, and
albumin, the patient underwent LT (Fig. 1). The ‘‘actual’’ as well
as the ‘‘real’’ MELD and MELD-Na scores at the time of LT are
reported in Fig. 2. After LT, in order to reduce the calcineurin
inhibitors (CNIs) -induced nephrotoxicity, a low dose of tacroli-
mus (target trough tacrolimus level <5 ng/ml) was used together
with mycophenolate mofetil. Eleven months after LT the patient
is in good clinical condition with normal renal function (Fig. 3).0
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Fig. 3. Time course of glomerular ﬁltration rate calculated on the basis of the Modiﬁcation of Diet in Renal Disease (MDRD) equation after LT in the three patients.
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In February 2010 a 52-year-old man with a history of alcohol-
related cirrhosis (abstinent from 2009) was admitted to our Liver
Unit for refractory ascites and hepatic encephalopathy. On admis-
sion the patient presented ascites, severe hyponatremia
(112 mmol/L) and renal impairment (serum creatinine
236 lmol/L; 2.67 mg/dl). Since the laboratory examinations car-
ried out ten days before hospital admission showed that he had
a normal renal function (serum creatinine 87 lmol/L; 0.98 mg/
dl), a diagnosis of type 1 HRS was made according to ICA diagnos-
tic criteria [2]. At this point terlipressin was administered as
intravenous boluses at the daily dose of 3 mg associated with
20–40 g/day of albumin [2]. Renal function improved and after
10 days terlipressin and albumin were discontinued. During the
following 72 h renal function progressively worsened, even with-
out there being evidence of a precipitating factor. Therefore,
treatment with terlipressin and albumin was restarted, produc-
ing a completely new response within ﬁve days. However, after
the withdrawal of terlipressin and albumin a new recurrence of
type 1 HRS occurred, making it necessary to restart the treat-
ment. During the following twenty days, the patient maintained
a good renal function and a normal serum sodium level even if
an increase of the daily dose of terlipressin up to 4 mg was
required to control another increase in serum creatinine. Another
attempt at discontinuing treatment, even in a step-wise fashion,
was soon followed by a further impairment of renal function, so
on day 44 after admission the patient was still on treatment with
terlipressin and albumin (Fig. 4). No terlipressin-related side
effect was observed. On day 45, a request of ‘‘early’’ LT was
advanced. On day 46 the patient underwent LT. The ‘‘actual’’
MELD score, the ‘‘actual’’ MELD-Na score as well as the ‘‘real’’Journal of Hepatology 201scores at the time of LT are reported on Fig. 2. After LT, in order
to counteract CNIs-induced nephrotoxicity, mycophenolate
mofetil and reduced dose tacrolimus were administered. Seven
months after LT the patient is in good clinical condition and his
renal function is normal (Fig. 3).
Case 3
In May 2010 a 46-year-old man with HCV and alcohol-related cir-
rhosis (abstinent from 2009) was admitted to our Liver Unit for
refractory ascites and urinary trait infection (UTI). On admission
serum creatinine was normal (97 lmol/L; 1.10 mg/dl). UTI was
successfully treated with antibiotic therapy. After ten days the
patient developed cellulitis and his renal function rapidly wors-
ened (serum creatinine 225 lmol/L; 2.55 mg/dl). The diagnosis
of type 1 HRS was made according to ICA criteria. Treatment with
i.v. terlipressin and albumin was started together with antibiotic
therapy with a complete response in 9 days. At the same time the
ongoing treatment with propanolol was discontinued. On day 19
after admission terlipressin and albumin were discontinued.
Within the following 48 h renal function worsened, despite the
resolution of the infection, and terlipressin and albumin were
restarted. A further attempt to withdraw the treatment at
27 day failed. Consequently, the treatment was started again
and a request for ‘‘early transplant’’ was submitted. Treatment
with telipressin and albumin was no longer discontinued. The
daily dose of terlipressin was transiently doubled to cope with
another increase in the serum creatinine level. Therefore, after
44 days from the onset of the ﬁrst episode of type 1 HRS, while
still under treatment (Fig. 5), the patient was transplanted. The
‘‘actual’’ as well as the ‘‘real’’ MELD and MELD-Na scores at the
time of LT are reported on Fig. 2. Mycophenolate mofetil and1 vol. 55 j 491–496 493
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Fig. 4. Time course of serum creatinine and treatment with terlipressin and albumin in patient 2. The daily dose of terlipressin is also indicated. Albumin was
administered at the dose of 20–40 g/day for the duration of treatment with terlipressin. Dotted line indicates a 133 lmol/L value of serum creatinine. Dashed line indicates
a 226 lmol/L value of serum creatinine.
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Fig. 5. Time course of serum creatinine and treatment with terlipressin and albumin in patient 3. The dose of terlipressin is also indicated. Albumin was administered
at the dose of 20–40 g/day for the duration of treatment with terlipressin. Dotted line indicates a 133 lmol/L value of serum creatinine. Dashed line indicates a 226 lmol/L
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reduced dose cyclosporine were used as immunosuppressive
strategy after LT. Six months after LT he is in good clinical condi-
tion with a normal renal function (Fig. 3).Discussion
Type 1 HRS is a severe complication of cirrhosis with a highly
negative impact on prognosis. It has been shown that terlipressin
plus albumin is an effective treatment for type 1 HRS and that a
good response to this treatment is associated with an improve-
ment of both transplant-free survival and outcome of LT [4]. It
is said that the mean time of treatment in responders is about
10–12 days and that a treatment longer than 14 days is not justi-
ﬁable in case of no response or partial response [2]. Nevertheless,
type 1 HRS can recur in up to 20% of patients, so that re-treat-
ment with terlipressin and albumin is recommended in these
patients [1]. Despite the efﬁcacy of the treatment with terlipres-
sin and albumin in patients with type 1 HRS, there are concerns
about its impact on the timing of LT. Since 2002, MELD score has
determined the priority in liver allocation in many countries. The
existence of an exception to MELD was recognized in the initial
development of the MELD-based liver allocation policy [5]. Type
1 HRS is not speciﬁcally considered to be among the exceptions to
the MELD-based allocation system, even though it has been
clearly demonstrated that patients with HRS have a worse out-
come for any given MELD score than other patients with cirrhosis
[6,7]. In addition, paradoxically, the response to treatment with
terlipressin and albumin, reduces the MELD score and negatively
affects the position of patients in the waiting list [3]. This prob-
lem cannot be solved considering the MELD Na score, since hypo-
natremia, which is frequent in patients with type 1 HRS, has been
shown to be improved by the treatment with vasoconstrictors
and albumin [8]. The extreme situation in this paradox is repre-
sented by patients with continuous recurrence of type 1 HRS
who need a long-term treatment with terlipressin and albumin.
To date, the prognostic impact of continuous recurrence of type
1 HRS has never been evaluated. Nevertheless, it is not unreason-
able to speculate that it is even worse than that related to a single
episode of HRS.
Here we have described three cases involving the long term
use of terlipressin and albumin as a bridge to LT, in which we
considered the absolute dependence on treatment as an excep-
tion to the MELD. These three cases were observed among a
cohort of 24 consecutive patients who were admitted for type 1
HRS in our Liver Unit or who developed it during hospitalization.
These three patients also represent the 60% of those with recur-
rent type 1 HRS after the withdrawal of the treatment. For the
purposes of this report, we deﬁne as continuous recurrence of
type 1 HRS a relapse of type 1 HRS more than once within 72 h
after the discontinuation of treatment. Since it has been stated
that 14 days is the maximum time necessary to treat an episode
of type 1 HRS in partial responders [2], we consider the adminis-
tration of terlipressin and albumin for more than 30 days as ‘‘long
term’’ treatment, because it covers more than two subsequent
episodes of type 1 HRS. Three preliminary observations can be
made based on our experience. The ﬁrst is that continuous recur-
rence of type 1 HRS is not a rare event. The second is that the way
to discontinue treatment with terlipressin and albumin does not
seem to affect the recurrence of type 1 HRS. The third is that a
long-term treatment with terlipressin and albumin is effectiveJournal of Hepatology 201and well tolerated in treating the continuous recurrence of type
1 HRS.
To the best of our knowledge only eight patients who received
long-term treatment with terlipressin and albumin have been
reported [3,9,10]. Only 5 out of these eight patients underwent
LT, and only three of them were still alive 6 months after LT.
The remaining two patients died soon after LT from septic shock
or massive bleeding. For these two patients, the poor outcome
after LT was attributed by the Authors to the high MELD score
at the time of LT [3]. Taking into account the waiting time before
LT and the lack of a request for an ‘‘early’’ transplant, it can be
observed that the response to therapy probably delayed the time
of LT in these patients. In fact, they were transplanted only when
they had reached a MELD score of 23 and 25, respectively, despite
a good renal function after a ‘‘dramatic clinical course which was
characterized by recurrent infections and bleeding complica-
tions’’ [3]. In order to support this concept, taking into account
the value of serum creatinine before the last re-treatment with
terlipressin and albumin, the ‘‘real’’ MELD score in these two
patients would have been 31 and 33, respectively. Consequently,
the two patients who died soon after LT had waited for the graft
more than 2 months from the ﬁrst episode of type 1 HRS with a
‘‘real’’ MELD scoreP 30, which is known to be associated with
an increased mortality after LT [11].
In our patients, the inability to discontinue terlipressin and
albumin for continuous recurrence of HRS was used as a criterion
for proposing these patients for an ‘‘early transplant’’, as previ-
ously described in Case 1. Using this procedure, all our patients
were transplanted within 2 months after the development of
the ﬁrst type 1 HRS with an actual MELD within 17–19 and a
‘‘real’’ MELD within 25–30 respectively (Fig. 2). In keeping with
the previous observation [4], the outcome of LT in our patients
was excellent since (a) all them are alive at P6 months after
LT, (b) none required renal replacement therapy after LT and (c)
none of them developed chronic kidney disease [12] after LT.
We realize that the request for an ‘‘early transplant’’ is an option
limited to our country, which does occur in most other countries.
We are also aware that the decision-making in such a critical sit-
uation cannot be entrusted simply to a gentlemen’s agreement
among different transplant centers. Therefore, while we wait
for the acceptance by the transplant community of the use of
prognostic formulae including not only MELD score and serum
sodium, but also the occurrence of HRS [7], we propose that at
least a long-term treatment of type 1 HRS with terlipressin and
albumin for the continuous recurrence of this complication is
considered as a priority criterion for organ allocation. This can
be made either by considering the long term treatment of type
1 HRS as an exception to MELD or including it in the calculation
of MELD score already provided for renal replacement therapy.
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